EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $33.00 by Analysts at Robert W. Baird

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) had its target price decreased by Robert W. Baird from $38.00 to $33.00 in a research note issued on Monday,Benzinga reports. The firm presently has an "outperform" rating on the stock. Robert W. Baird's target price points to a potential upside of 179.19% from the stock's current price.

Other research analysts have also issued reports about the stock. Jefferies Financial Group began coverage on shares of EyePoint Pharmaceuticals in a research note on Wednesday, August 28th. They issued a "buy" rating and a $15.00 price objective on the stock. JPMorgan Chase & Co. dropped their price target on EyePoint Pharmaceuticals from $32.00 to $29.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 13th. StockNews.com raised EyePoint Pharmaceuticals to a "sell" rating in a research report on Saturday, September 21st. Chardan Capital boosted their target price on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the company a "buy" rating in a report on Friday. Finally, Scotiabank assumed coverage on EyePoint Pharmaceuticals in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $18.00 price target for the company. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $28.00.

EyePoint Pharmaceuticals Stock Performance

NASDAQ EYPT traded up $0.19 on Monday, reaching $11.82. The stock had a trading volume of 334,697 shares, compared to its average volume of 937,566. The stock has a market cap of $632.61 million, a P/E ratio of -5.82 and a beta of 1.50. EyePoint Pharmaceuticals has a 12-month low of $5.86 and a 12-month high of $30.99. The business's 50-day moving average price is $9.50 and its 200 day moving average price is $9.97.

Institutional Trading of EyePoint Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Ameritas Investment Partners Inc. raised its position in shares of EyePoint Pharmaceuticals by 44.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,719 shares of the company's stock worth $77,000 after purchasing an additional 1,136 shares during the last quarter. ProShare Advisors LLC purchased a new stake in shares of EyePoint Pharmaceuticals in the first quarter valued at $209,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of EyePoint Pharmaceuticals by 68.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company's stock valued at $82,000 after acquiring an additional 4,172 shares during the last quarter. Greenwich Wealth Management LLC purchased a new stake in EyePoint Pharmaceuticals during the 2nd quarter worth about $94,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in EyePoint Pharmaceuticals by 271.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company's stock valued at $95,000 after purchasing an additional 7,953 shares during the last quarter. Hedge funds and other institutional investors own 99.41% of the company's stock.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.